Unichem Laboratories is currently trading at Rs. 136.00, up by 3.80 points or 2.87% from its previous closing of Rs. 132.20 on the BSE.
The scrip opened at Rs. 134.95 and has touched a high and low of Rs. 136.40 and Rs. 133.00 respectively. So far 1707 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 185.00 on 13-May-2011 and a 52 week low of Rs. 101.15 on 13-Dec-2011.
Last one week high and low of the scrip stood at Rs. 144.00 and Rs. 130.00 respectively. The current market cap of the company is Rs. 1194.05 crore.
The promoters holding in the company stood at 49.58% while Institutions and Non-Institutions held 13.77% and 36.65% respectively.
Unichem Laboratories has registered 56.53% jump in its net profit at Rs 23.23 crore for the fourth quarter ended March 31, 2012. The company had posted a net profit of Rs 14.84 crore for the same in fiscal 2010-11.
The pharmaceutical company’s total income stood at Rs 192.97 crore for the quarter ended March 31, 2012 as against Rs 178.10 crore in the year-ago period, up by 8.35%.
However, net profits of the Mumbai-based firm declined by 23.99% to Rs 82.46 crore for the financial year ended March 31, 2012 from Rs 108.49 crore in the year-ago period.
Total income of the company stood at Rs 803.18 crore for the year ended March 31, 2012 as against Rs 764.73 crore in the previous fiscal, rose 5.01%.
Apart from its formulations business, Unichem also manufactures active pharmaceutical ingredients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: